KalVista Pharma (KALV)
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candid...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 27.000
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 27.000
- Volume Ratio
- 0.00
- Turnover Ratio
- --
KalVista Pharma Analyst Rating
View moreForecast & Rating
May 15, 2026Price forecast
$28.605.93%
Forecast & RatingHold
7analysts
- Strong buy14.29%
- Buy0.00%
- Hold85.71%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 11 at 07:17 AM
DRI Healthcare receives put price of about US$178 million for EKTERLY royalty interest
- Quartr · Aug 10 at 09:28 AM
DHT.U: Record Q2 growth, strong liquidity, and strategic asset monetization drive robust outlook
- PUBT · Jul 10 at 08:29 AM
DRI Healthcare exercises put option on EKTERLY royalty stake for net US$178 million
- Market Beat · Jun 19 at 05:25 AM
Seven Fleet Capital Management LP Buys New Stake in KalVista Pharmaceuticals, Inc. $KALV
- Market Beat · Jun 16 at 05:47 AM
387,968 Shares in KalVista Pharmaceuticals, Inc. $KALV Bought by Spruce Street Capital LP
- Market Beat · Jun 14 at 07:32 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update
